SUBSCRIBE
FDA approves Lundbeck’s VYEPTI™ (eptinezumab-jjmr) – the first and only intravenous preventive treatment for migraine
Lundbeck today announced that VYEPTI™ (eptinezumab-jjmr) has been approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults and will be available in April 2020.
0
ABOUT THE NEWSROOM
Here you will find media contacts, plus the latest news, stories and insights from Lundbeck US. Lundbeck is a global pharmaceutical company solely focused on the brain, and our 900+ U.S. employees are committed to improving the lives of people affected by psychiatric and neurological disorders.
